首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
【2h】

Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials

机译:早期应用小剂量糖皮质激素可改善急性呼吸窘迫综合征:一项随机对照试验的荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Previous clinical trials have investigated the effect of glucocorticoid therapy in acute respiratory distress syndrome (ARDS), with controversial results, particularly with regard to the early administration of low dose glucocorticoid. The present meta-analysis aimed to assess whether the application of glucocorticoid was able to reduce mortality in patients with ARDS. A literature search was performed using online databases, including MEDLINE, Embase, Cochrane and CNKI regardless of whether the studies were published in English or Chinese. Following assessment via inclusion and exclusion criteria, two reviewers screened controlled randomized trials which investigated glucocorticoid therapy in ARDS patients and independently extracted data. The quality of all of the included trials was evaluated based on blinding, randomization and other methods. A total of 14 studies with 1,441 patients met the inclusion criteria. The results of the meta-analysis demonstrated that glucocorticoid significantly reduced the overall mortality of patients with ARDS [relative ratio (RR), 0.68; 95% confidence interval (CI), 0.50–0.91; P<0.05], particularly with a low-dose of glucocorticoid (RR, 0.57; 95% CI, 0.39–0.84; P<0.05) at the early phase of ARDS (RR, 0.37; 95% CI, 0.16–0.86; P<0.05), and a longer duration of steroids (RR, 0.44; 95% CI, 0.30–0.64; P<0.05). Administration of steroids also significantly increased the number of days that patients remained alive and were off mechanical ventilation (RR, 3.08; 95% CI, 1.49–4.68; P<0.05) without significantly increasing the novel infection rate (RR, 1.00; 95% CI, 0.44–2.25; P<0.05). Due to inconsistencies and other limitations, the quality of the studies used for the meta-analysis of the effect of glucocorticoid on mortality was low. In conclusion, early use of low dose glucocorticoid may effectively reduce mortality in patients with ARDS. However, this conclusion may be affected by the limited quality of the studies included in the present meta-analysis.
机译:先前的临床试验已经研究了糖皮质激素治疗在急性呼吸窘迫综合征(ARDS)中的作用,并引起争议的结果,特别是在低剂量糖皮质激素的早期给药方面。本荟萃分析旨在评估糖皮质激素的应用是否能够降低ARDS患者的死亡率。文献检索是使用包括MEDLINE,Embase,Cochrane和CNKI在内的在线数据库进行的,无论该研究是用英文还是中文发表。通过纳入和排除标准进行评估后,两名评价者筛选了对照随机试验,该试验研究了ARDS患者的糖皮质激素治疗并独立提取数据。所有纳入试验的质量均基于盲法,随机化和其他方法进行评估。共有14项研究(含1,441例患者)符合纳入标准。荟萃分析的结果表明,糖皮质激素显着降低了ARDS患者的总死亡率[相对比(RR)为0.68; 95%置信区间(CI),0.50-0.91; P <0.05],尤其是ARDS早期低剂量糖皮质激素(RR,0.57; 95%CI,0.39–0.84; P <0.05)(RR,0.37; 95%CI,0.16-0.86; P <0.05),以及类固醇的持续时间更长(RR,0.44; 95%CI,0.30-0.64; P <0.05)。类固醇的给药还显着增加了患者存活和不进行机械通气的天数(RR,3.08; 95%CI,1.49–4.68; P <0.05),而没有显着增加新发感染率(RR,1.00; 95%) CI,0.44-2.25; P <0.05)。由于不一致和其他限制,用于糖皮质激素对死亡率影响的荟萃分析的研究质量较低。总之,低剂量糖皮质激素的早期使用可有效降低ARDS患者的死亡率。但是,该结论可能会受到本荟萃分析中研究质量有限的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号